Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease

The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn’s disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goal...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinisch, Walter, Gecse, Krisztina, Halfvarson, Jonas, Irving, Peter M, Jahnsen, Jørgen, Peyrin-Biroulet, Laurent, Rogler, Gerhard, Schreiber, Stefan, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737159/
https://www.ncbi.nlm.nih.gov/pubmed/32634212
http://dx.doi.org/10.1093/ibd/izaa078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737159/
https://www.ncbi.nlm.nih.gov/pubmed/32634212
http://dx.doi.org/10.1093/ibd/izaa078

Ejemplares similares